Publications by authors named "Morihiro Kondo"
Background: There is no standard therapy for hemodialysis (HD) patients with COVID-19. Data on remdesivir in HD patients with COVID-19 are scarce.
Methods: We retrospectively analyzed 25 HD patients with COVID-19 treated with remdesivir.
Article Synopsis
- The study aimed to investigate the effectiveness of nemolizumab, an anti-IL-31 receptor antibody, in treating uremic pruritus in Japanese hemodialysis patients, comparing it to a placebo and an oral medication, nalfurafine.
- Patients were divided into multiple groups receiving different doses of nemolizumab or placebo, with the primary goal being to measure changes in itching severity after 4 weeks.
- The results showed that while some patients noticed improvements in itching, the primary endpoint of significant efficacy was not achieved, although nemolizumab was generally well-tolerated without major safety issues.
Background: Recent research has focused on the roles of trace minerals such as zinc and copper. In 2017, oral zinc acetate was approved to treat zinc deficiency, and the next year, the Japanese Society for Clinical Nutrition developed the guidelines for diagnosis and treatment for zinc deficiency. Accordingly, hemodialysis patients began receiving zinc acetate when zinc deficiency was diagnosed.
View Article and Find Full Text PDFBackground: In order to keep up the optimal iron status in chronic hemodialysis patients, it is important to know how much iron is lost due to hemodialysis. Residual blood associated with the hemodialysis procedure together with blood sampling inevitably causes the loss of iron in chronic hemodialysis patients. Recent advances in hemodialysis techniques might have reduced this complication.
View Article and Find Full Text PDFAnti-diabetic agent-related hypoglycemia is a serious complication in type 2 diabetic patients on hemodialysis. Therefore, we assessed the efficacy and tolerability of 24 weeks of monotherapy with vildagliptin, a dipeptidyl peptidase four inhibitor, which is a new class of antidiabetic agent. This open-label, single-arm clinical trial was performed on 26 patients on hemodialysis.
View Article and Find Full Text PDF